$581 Million is the total value of BVF INC/IL's 26 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 62.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
LGND | Sell | LIGAND PHARMACEUTICALS INC | $136,491,000 | +0.7% | 3,153,665 | -12.9% | 23.48% | -10.7% |
ARRY | Sell | ARRAY BIOPHARMA INC | $60,456,000 | +19.6% | 9,719,589 | -12.7% | 10.40% | +6.1% |
RGLS | Sell | REGULUS THERAPEUTICS INC | $2,204,000 | -15.7% | 233,689 | -12.3% | 0.38% | -25.2% |
FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -151,406 | -100.0% | -0.18% | – |
ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -4,477,000 | -100.0% | -0.40% | – |
ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -153,500 | -100.0% | -0.53% | – |
PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -305,786 | -100.0% | -1.46% | – |
CYTK | Exit | CYTOKINETICS INC | $0 | – | -1,718,905 | -100.0% | -3.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
ARQULE INC | 27 | Q4 2019 | 4.8% |
CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-06-10 |
13F-HR | 2024-05-15 |
4 | 2024-05-13 |
13F-HR | 2024-02-14 |
4 | 2024-01-29 |
3 | 2024-01-26 |
4 | 2024-01-09 |
4 | 2023-12-20 |
4 | 2023-11-17 |
13F-HR | 2023-11-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.